{"result": {"id": "chatcmpl-463", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "EPC-EXOS is a company that has developed a new technology for improving mouse ischemic hindlimb perfusion. This technology utilizes a specific type of molecule, which enhances angiogenesis and promotes neovascularization.  The substance in question acts as a catalyst for neovascularization, utilizing cells to promote the growth of new blood vessels. \n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743303537, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 67, "prompt_tokens": 190, "total_tokens": 257, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we have the full context.\n\n#######\n-Data-\nEntities: \"EPC-EXOS\"\nDescription List: [\"A company that developed a new technology for improving mouse ischemic hindlimb perfusion\", \"A specific type of molecule that enhances angiogenesis\", \"A substance that promotes neovascularization\", \"A type of cells that are used to promote neovascularization\"]\n#######\nOutput:\n", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 500, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_summarize_6e3e35445bbd76cdee48f80173fc69388718bfdb925216a6f2bbfa7bc00995d4_v2"}